Segmentation, Major Trends, and Competitive Overview of the Non-Insulin Therapies for Diabetes Market

The market for non-insulin therapies in diabetes care is poised for significant expansion as new treatment options and technological advancements continue to evolve. As diabetes management shifts towards more personalized and digitally integrated approaches, the demand for alternative therapies beyond insulin is growing rapidly worldwide. This overview highlights the anticipated market size, key players, emerging trends, and segmentation within this dynamic healthcare sector.

Forecasted Expansion of the Non-Insulin Therapies for Diabetes Market
The global non-insulin therapies for diabetes market is projected to grow substantially, reaching a value of $28.39 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 5.9% during the forecast period. The expanding market is driven by increased utilization of non-insulin drug combinations, heightened adoption of GLP-1 and SGLT2 inhibitors, and the broadening reach of online pharmacy channels. Additionally, advancements in personalized medicine, digital health integration, and remote patient monitoring contribute significantly to this upward trend. Key market trends include the rising acceptance of personalized diabetes management, AI-powered glucose monitoring systems, telemedicine-enabled therapy solutions, implementation of data-driven clinical decision support tools, and the growing use of connected devices for remote care.

Download a free report of the non-insulin therapies for diabetes market report:
https://www.thebusinessresearchcompany.com/report/non-insulin-therapies-for-diabetes-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Industry Leaders in the Non-Insulin Therapies for Diabetes Market
Several major pharmaceutical companies are leading the non-insulin diabetes therapies market, including Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, and SatRx LLC.
In a notable development in August 2023, Eli Lilly and Company acquired Sigilon Therapeutics Inc. for $309.6 million. This acquisition aims to accelerate Lilly's research and development efforts in encapsulated cell therapies, such as SIG-002, targeting improved treatment options for type 1 diabetes patients. Sigilon Therapeutics, based in the United States, specializes in developing these innovative encapsulated cell therapy solutions.

New Developments and Emerging Trends in Non-Insulin Diabetes Treatments
The market is witnessing a surge in innovation, with leading firms focusing on next-generation sequencing technologies to enhance diabetes research and clinical efficiency. These advanced sequencing platforms are designed to be ultra-rapid and scalable, aiming to reduce costs and turnaround times while improving accuracy.
For example, in February 2025, Roche Holding AG introduced the Sequencing by Expansion (SBX) technology. This fully integrated sequencing platform uses a patented biochemical process that translates DNA or RNA sequences into measurable surrogate polymers called Xpandomers, enabling precise single-molecule nanopore sequencing. The SBX system offers ultra-fast, scalable sequencing and automated data analysis, delivering whole-genome sequencing results within hours rather than days, and minimizing manual intervention.

View the full non-insulin therapies for diabetes market report:
https://www.thebusinessresearchcompany.com/report/non-insulin-therapies-for-diabetes-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Comprehensive Segmentation of the Non-Insulin Therapies for Diabetes Market
The report breaks down the non-insulin therapies for diabetes market into several key segments:
1) By Type: Biguanides, Sulfonylureas, Thiazolidinediones (TZDs), DPP-4 Inhibitors, GLP-1 Analogs or Agonists, and SGLT2 Inhibitors.
2) By Route of Administration: Oral and Injectable forms.
3) By Application: Treatments for Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes.
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
5) By End User: Hospitals or Clinics, Homecare or Patients, and Other end users.
Further detailing includes subcategories such as Metformin and its combinations under Biguanides; Glimepiride, Glipizide, and Glyburide under Sulfonylureas; Pioglitazone and Rosiglitazone under TZDs; Sitagliptin, Saxagliptin, and Linagliptin under DPP-4 Inhibitors; Exenatide, Liraglutide, and Dulaglutide under GLP-1 Analogs or Agonists; and Canagliflozin, Dapagliflozin, and Empagliflozin under SGLT2 Inhibitors.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.